Immune checkpoint inhibitors: recent progress and potential biomarkers.
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. · 2018
Read Immune checkpoint inhibitors: recent progress and potential biomarkers. by Darvin P, Toor SM, Sasidharan Nair V, Elkord E. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6292890.txt.
Description
Darvin and co-authors review immune checkpoint inhibitors, a new class of cancer drugs. The review appeared in Experimental and Molecular Medicine. Tumors can switch on immune checkpoints to hide from attack. Antibodies that block these checkpoints have changed cancer care. Two main targets are PD-1 and CTLA-4.
The authors report strong gains for some patients with these drugs. Yet many patients do not respond at all. Others suffer immune side effects. The review thus focuses on biomarkers that could predict response. Candidates include PD-L1 levels, new antigens, and gene signatures. Better tests would help doctors pick the right patients for treatment.
Catalog record
| CREATOR | Darvin P, Toor SM, Sasidharan Nair V, Elkord E. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |